Article
A nasal vaccine elicits protective CD8+ T cell immunity against antigen shifted SARS-CoV-2 virus - Nature Immunology
Rating:
0.0
Views:
23
Likes:
1
Library:
1
In this study, we developed an adenoviral-vectored vaccine that targets the spike protein of BA.5 Omicron SARS-CoV-2. When nasally delivered in mice and hamsters, the vaccine stimulated mucosal antibody production and CD8+ T cell responses, and demonstrated protection against several SARS-CoV-2 strains, including the antigenically distant Omicron XBB.1.5 strain.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value